Evidence map›Paper›PMID 41876949›Full record

SynthesisCancer medicine2026

Neoadjuvant Therapy for Locally Advanced Gastric/Gastroesophageal Junction Adenocarcinoma: Current Status, Challenges, and Future Perspectives.

Jiaqi Zhou, Chengwang Guo, Mingze Zhang, Xi Guo, Jihong Wang, Xiaojun Liu, Peng Nie, Yuntao Ma

Abstract readSystematic Review
In one paragraph

Synthesis in Cancer medicine, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Jiaqi ZhouThe First Clinical School of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Chengwang GuoThe First Clinical School of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.ORCID https://orcid.org/0009-0001-9362-7261
Mingze ZhangThe First Clinical School of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Xi GuoThe First Clinical School of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Jihong WangDepartment of Gastric Tumor Surgery, Gansu Wuwei Tumor Hospital, Wuwei, Gansu, China.
Xiaojun LiuThe First Clinical School of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.
Peng NieDepartment of Gastric Tumor Surgery, Gansu Wuwei Tumor Hospital, Wuwei, Gansu, China.
Yuntao MaThe First Clinical School of Gansu University of Chinese Medicine, Lanzhou, Gansu, China.

Funding

Science and Technology Department of Gansu Province 24JRRA885Wu Jieping Medical Foundation Scientific Research Grant 320.6750.2025-13-59Wuwei Clinical Research Center for Gastric 2023LC5011
6 · The paper itself

Abstract

Gastric cancer remains a leading cause of cancer-related mortality worldwide, with locally advanced gastric/gastroesophageal junction adenocarcinoma posing significant therapeutic challenges. Neoadjuvant therapy has emerged as a critical strategy to improve surgical outcomes and long-term survival by reducing tumor burden and eradicating micrometastases. This systematic review integrates evidence from more than 100 clinical trials and 20 meta-analyses published in recent years. It focuses on new advances in neoadjuvant therapies for gastric cancer, including chemotherapy, radiotherapy, immunotherapy, and targeted therapies, while highlighting emerging combination strategies and unresolved clinical dilemmas.

Indexed as

AdenocarcinomaEsophageal NeoplasmsEsophagogastric JunctionNeoadjuvant TherapyStomach NeoplasmsHumansImmunotherapychemotherapygastric cancerimmunotherapyneoadjuvant therapytargeted therapy

Identifiers

PMID41876949
PMCPMC13140983

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.